Smad3 Induces Atrogin-1, Inhibits mTOR and Protein Synthesis, and Promotes Muscle Atrophy In Vivo
Open accessThe DOI matches its Crossref record; 24 of the 24 references it cites were found in a registry or an index.
Abstract
Myostatin, a member of the TGF superfamily, is sufficient to induce skeletal muscle atrophy. Myostatin-induced atrophy is associated with increases in E3-ligase atrogin-1 expression and protein degradation and decreases in Akt/mechanistic target of rapamycin (mTOR) signaling and protein synthesis. Myostatin signaling activates the transcription factor Smad3 (Small Mothers Against Decapentaplegic), which has been shown to be necessary for myostatin-induced atrogin-1 expression and atrophy; however, it is not known whether Smad3 is sufficient to induce these events or whether Smad3 simply plays a permissive role. Thus, the aim of this study was to address these questions with an in vivo model. To accomplish this goal, in vivo transfection of plasmid DNA was used to create transient transgenic mouse skeletal muscles, and our results show for the first time that Smad3 expression is sufficient to stimulate atrogin-1 promoter activity, inhibit Akt/mTOR signaling and protein synthesis, and induce muscle fiber atrophy. Moreover, we propose that Akt/mTOR signaling is inhibited by a Smad3-induced decrease in microRNA-29 (miR-29) expression and a subsequent increase in the translation of phosphatase and tensin homolog (PTEN) mRNA. Smad3 is also sufficient to inhibit peroxisome proliferator-activated receptor-γ coactivator-1α (PGC1α) promoter activity and to increase FoxO (Forkhead Box Protein, Subclass O)-mediated signaling and the promoter activity of plasminogen activator inhibitor 1 (PAI-1). Combined, this study provides the first evidence that Smad3 is sufficient to regulate many of the events associated with myostatin-induced atrophy and therefore suggests that Smad3 signaling may be a viable target for therapies aimed at preventing myostatin-induced muscle atrophy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Ford, E. S., Giles, W. H., & Dietz, W. H. (2002) · JAMA · doi:10.1001/jama.287.3.356 · Cited by 6,698
The interaction of TIGIT with PVR and PVRL2 inhibits human NK cell cytotoxicity
Stanietsky, N., Simic, H., Arapovic, J., Toporik, A., Levy, O., Novik, A., Levine, Z., Beiman, M., Dassa, L., Achdout, H., et al. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0903474106 · Cited by 3,524
Identification of ubiquitin ligases required for skeletal muscle atrophy.
Bodine, S. C., Latres, E., Baumhueter, S., Lai, V. K.-M., Nunez, L., Clarke, B. A., Poueymirou, W. T., Panaro, F. J., Na, E., Dharmarajan, K., et al. (2001) · Science · doi:10.1126/science.1065874 · Cited by 3,521
Sandri, M., Sandri, C., Gilbert, A., Skurk, C., Calabria, E., Picard, A., Walsh, K., Schiaffino, S., Lecker, S. H., & Goldberg, A. L. (2004) · Cell · doi:10.1016/s0092-8674(04)00400-3 · Cited by 3,012 · cited 2×
“It is unclear, however, whether this Smad3-induced activation of the atrogin-1 gene is due to direct Smad3 binding to the atrogin-1 promoter and/or to Smad3-mediated activation of FoxO signaling (69, 70).”
BackgroundStitt, T. N., Drujan, D., Clarke, B. A., Panaro, F., Timofeyva, Y., Kline, W. O., Gonzalez, M., Yancopoulos, G. D., & Glass, D. J. (2004) · Molecular Cell · doi:10.1016/s1097-2765(04)00211-4 · Cited by 1,964
SUnSET, a nonradioactive method to monitor protein synthesis
Schmidt, E. K., Clavarino, G., Ceppi, M., & Pierre, P. (2009) · Nature Methods · doi:10.1038/nmeth.1314 · Cited by 1,706
Mechanisms regulating skeletal muscle growth and atrophy
Schiaffino, S., Dyar, K. A., Ciciliot, S., Blaauw, B., & Sandri, M. (2013) · The FEBS Journal · doi:10.1111/febs.12253 · Cited by 1,492 · cited 2×
“(24, 26); however, the mechanism responsible for”
BackgroundCellular and molecular mechanisms of muscle atrophy
Bonaldo, P., & Sandri, M. (2013) · Disease Models & Mechanisms · doi:10.1242/dmm.010389 · Cited by 1,284
Sandri, M., Lin, J., Handschin, C., Yang, W., Arany, Z. P., Lecker, S. H., Goldberg, A. L., & Spiegelman, B. M. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0607795103 · Cited by 974
Myostatin reduces Akt/TORC1/p70S6K signaling, inhibiting myoblast differentiation and myotube size
Trendelenburg, A. U., Meyer, A., Rohner, D., Boyle, J., Hatakeyama, S., & Glass, D. J. (2009) · American Journal of Physiology-Cell Physiology · doi:10.1152/ajpcell.00105.2009 · Cited by 792
Srikanthan, P., & Karlamangla, A. S. (2011) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2011-0435 · Cited by 785
Protection from obesity and diabetes by blockade of TGF-β/smad3 signaling
Yadav, H., Quijano, C., Kamaraju, A. K., Gavrilova, O., Malek, R., Chen, W., Zerfas, P., Zhigang, D., Wright, E. C., Stuelten, C., et al. (2011) · Cell Metabolism · doi:10.1016/j.cmet.2011.04.013 · Cited by 709
Gonzalez-Cadavid, N. F., Taylor, W. E., Yarasheski, K., Sinha-Hikim, I., Ma, K., Ezzat, S., Shen, R., Lalani, R., Asa, S., Mamita, M., et al. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.25.14938 · Cited by 571
Smad2 and 3 transcription factors control muscle mass in adulthood
Sartori, R., Milan, G., Patron, M., Mammucari, C., Blaauw, B., Abraham, R., & Sandri, M. (2009) · American Journal of Physiology-Cell Physiology · doi:10.1152/ajpcell.00104.2009 · Cited by 517 · cited 9×
“Nevertheless, this finding is also consistent with the study of Sartori et al (25), which showed that expression of c.”
BackgroundResultInfluentialYAP mediates crosstalk between the Hippo and PI(3)K–TOR pathways by suppressing PTEN via miR-29
Tumaneng, K., Schlegelmilch, K., Russell, R. C., Yimlamai, D., Basnet, H., Mahadevan, N., Fitamant, J., Bardeesy, N., Camargo, F. D., & Guan, K.-L. (2012) · Nature Cell Biology · doi:10.1038/ncb2615 · Cited by 453
Increased secretion and expression of myostatin in skeletal muscle from extremely obese women
Hittel, D. S., Berggren, J. R., Shearer, J., Boyle, K., & Houmard, J. A. (2009) · Diabetes · doi:10.2337/db08-0943 · Cited by 324
Myostatin/activin pathway antagonism: molecular basis and therapeutic potential
Han, H. Q., Zhou, X., Mitch, W. E., & Goldberg, A. L. (2013) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/j.biocel.2013.05.019 · Cited by 314 · cited 1×
“for attenuating atrophy, increasing muscle mass, reducing fibrosis, and improving muscle regeneration in various pathological conditions (17).”
BackgroundShan, T., Liang, X., Bi, P., & Kuang, S. (2013) · The FASEB Journal · doi:10.1096/fj.12-225755 · Cited by 301
The role of skeletal muscle mTOR in the regulation of mechanical load‐induced growth
Goodman, C. A., Frey, J. W., Mabrey, D. M., Jacobs, B. L., Lincoln, H. C., You, J., & Hornberger, T. A. (2011) · The Journal of Physiology · doi:10.1113/jphysiol.2011.218255 · Cited by 297
Self-citationRegulation of Muscle Mass by Follistatin and Activins
Lee, S.-J., Lee, Y.-S., Zimmers, T. A., Soleimani, A., Matzuk, M. M., Tsuchida, K., Cohn, R. D., & Barton, E. R. (2010) · Molecular Endocrinology · doi:10.1210/me.2010-0127 · Cited by 273 · cited 1×
“Interestingly, both TGF- and activin A are also implicated in skeletal muscle atrophy and fibrosis (21, 22).”
BackgroundMeasuring Protein Synthesis With SUnSET: A Valid Alternative to Traditional Techniques?
Goodman, C. A., & Hornberger, T. A. (2013) · Exercise and Sport Sciences Reviews · doi:10.1097/jes.0b013e3182798a95 · Cited by 233
Self-citationBrault, J. J., Jespersen, J. G., & Goldberg, A. L. (2010) · Journal of Biological Chemistry · doi:10.1074/jbc.m110.113092 · Cited by 217
Mechanistic Links Between Oxidative Stress and Disuse Muscle Atrophy
Powers, S. K., Smuder, A. J., & Criswell, D. S. (2011) · Antioxidants & Redox Signaling · doi:10.1089/ars.2011.3973 · Cited by 199 · cited 1×
“Therefore, a decrease in PGC1 expression could contribute to muscle atrophy via a reduced repression of atrophy genes and/or indirectly by impairing mitochondrial function and fusion and increasing energy and oxidative stress (77, 78).”
BackgroundEisele, P. S., Salatino, S., Sobek, J., Hottiger, M. O., & Handschin, C. (2013) · Journal of Biological Chemistry · doi:10.1074/jbc.m112.375253 · Cited by 187
Research works printed but not linked: 59
- Goodman, 2011, Recent progress toward understanding the molecular mechanisms that regulate skeletal muscle mass, Cell Signal, 23, 1896, 10.1016/j.cellsig.2011.07.013 · DOI · Paper page
- Lynch, 2004, Tackling Australia's future health problems: developing strategies to combat sarcopenia: age-related muscle wasting and weakness, Intern Med J, 34, 294, 10.1111/j.1444-0903.2004.00568.x · DOI · Paper page
- Aversa, 2012, Changes in myostatin signaling in non-weight-losing cancer patients, Ann Surg Oncol, 19, 1350, 10.1245/s10434-011-1720-5 · DOI
- Léger, 2008, Human sarcopenia reveals an increase in SOCS-3 and myostatin and a reduced efficiency of Akt phosphorylation, Rejuvenation Res, 11, 163B, 10.1089/rej.2007.0588 · DOI · Paper page
- Bish, 2011, Myostatin is elevated in congenital heart disease and after mechanical unloading, PLoS ONE, 6, e23818, 10.1371/journal.pone.0023818 · DOI
- Gustafsson, 2010, Effects of 3 days unloading on molecular regulators of muscle size in humans, J Appl Physiol, 109, 721, 10.1152/japplphysiol.00110.2009 · DOI · Paper page
- Ju, 2012, Serum myostatin levels and skeletal muscle wasting in chronic obstructive pulmonary disease, Respir Med, 106, 102, 10.1016/j.rmed.2011.07.016 · DOI · Paper page
- Verzola, 2011, Apoptosis and myostatin mRNA are upregulated in the skeletal muscle of patients with chronic kidney disease, Kidney Int, 79, 773, 10.1038/ki.2010.494 · DOI
- Durieux, 2007, Ectopic expression of myostatin induces atrophy of adult skeletal muscle by decreasing muscle gene expression, Endocrinology, 148, 3140, 10.1210/en.2006-1500 · DOI · Paper page
- Li, 2008, Myostatin Directly Regulates Skeletal Muscle Fibrosis, J Biol Chem, 283, 19371, 10.1074/jbc.M802585200 · DOI · Paper page
- Zhu, 2007, Relationships between transforming growth factor-β1, myostatin, and decorin: implications for skeletal muscle fibrosis, J Biol Chem, 282, 25852, 10.1074/jbc.M704146200 · DOI · Paper page
- Elkasrawy, 2012, Immunolocalization of myostatin (GDF-8) following musculoskeletal injury and the effects of exogenous myostatin on muscle and bone healing, J Histochem Cytochem, 60, 22, 10.1369/0022155411425389 · DOI
- Elkina, 2011, The role of myostatin in muscle wasting: an overview, J Cachexia Sarcopenia Muscle, 2, 143, 10.1007/s13539-011-0035-5 · DOI · Paper page
- Walton, 2012, New insights into the mechanisms of activin action and inhibition, Mol Cell Endocrinol, 359, 2, 10.1016/j.mce.2011.06.030 · DOI
- Tsuchida, 2008, Signal transduction pathway through activin receptors as a therapeutic target of musculoskeletal diseases and cancer, Endocr J, 55, 11, 10.1507/endocrj.KR-110 · DOI · Paper page
- Mendias, 2012, Transforming growth factor-β induces skeletal muscle atrophy and fibrosis through the induction of atrogin-1 and scleraxis, Muscle Nerve, 45, 55, 10.1002/mus.22232 · DOI · Paper page
- Ross, 2008, How the Smads regulate transcription, Int J Biochem Cell Biol, 40, 383, 10.1016/j.biocel.2007.09.006 · DOI · Paper page
- Lokireddy, 2011, Myostatin induces degradation of sarcomeric proteins through a Smad3 signaling mechanism during skeletal muscle wasting, Mol Endocrinol, 25, 1936, 10.1210/me.2011-1124 · DOI · Paper page
- Lokireddy, 2011, Myostatin promotes the wasting of human myoblast cultures through promoting ubiquitin-proteasome pathway-mediated loss of sarcomeric proteins, Am J Physiol Cell Physiol, 301, C1316, 10.1152/ajpcell.00114.2011 · DOI · Paper page
- Lokireddy, 2012, Identification of atrogin-1-targeted proteins during the myostatin-induced skeletal muscle wasting, Am J Physiol Cell Physiol, 303, C512, 10.1152/ajpcell.00402.2011 · DOI · Paper page
- Taylor, 2001, Myostatin inhibits cell proliferation and protein synthesis in C2C12 muscle cells, Am J Physiol Endocrinol Metab, 280, E221, 10.1152/ajpendo.2001.280.2.E221 · DOI · Paper page
- Welle, 2006, Myofibrillar protein synthesis in myostatin-deficient mice, Am J Physiol Endocrinol Metab, 290, E409, 10.1152/ajpendo.00433.2005 · DOI · Paper page
- Welle, 2009, Stimulation of skeletal muscle myofibrillar protein synthesis, p70 S6 kinase phosphorylation, and ribosomal protein S6 phosphorylation by inhibition of myostatin in mature mice, Am J Physiol Endocrinol Metab, 296, E567, 10.1152/ajpendo.90862.2008 · DOI · Paper page
- Welle, 2011, Effect of postdevelopmental myostatin depletion on myofibrillar protein metabolism, Am J Physiol Endocrinol Metab, 300, E993, 10.1152/ajpendo.00509.2010 · DOI
- Rodriguez, 2011, Myostatin inactivation increases myotube size through regulation of translational initiation machinery, J Cell Biochem, 112, 3531, 10.1002/jcb.23280 · DOI · Paper page
- Hulmi, 2013, Muscle protein synthesis, mTORC1/MAPK/Hippo signaling, and capillary density are altered by blocking of myostatin and activins, Am J Physiol Endocrinol Metab, 304, E41, 10.1152/ajpendo.00389.2012 · DOI · Paper page
- Lagirand-Cantaloube, 2008, The initiation factor eIF3-f is a major target for Atrogin1/MAFbx function in skeletal muscle atrophy, EMBO J, 27, 1266, 10.1038/emboj.2008.52 · DOI · Paper page
- Amirouche, 2009, Down-regulation of Akt/mammalian target of rapamycin signaling pathway in response to myostatin overexpression in skeletal muscle, Endocrinology, 150, 286, 10.1210/en.2008-0959 · DOI · Paper page
- Zhou, 2012, Inhibition of miR-29 by TGF-beta-Smad3 signaling through dual mechanisms promotes transdifferentiation of mouse myoblasts into myofibroblasts, PLoS ONE, 7, e33766, 10.1371/journal.pone.0033766 · DOI
- Kong, 2011, Upregulated microRNA-29a by hepatitis B virus X protein enhances hepatoma cell migration by targeting PTEN in cell culture model, PLoS ONE, 6, e19518, 10.1371/journal.pone.0019518 · DOI · Paper page
- Wang, 2011, miR-29b regulates migration of human breast cancer cells, Mol Cell Biochem, 352, 197, 10.1007/s11010-011-0755-z · DOI
- Goodman, 2010, A phosphatidylinositol 3-kinase/protein kinase B-independent activation of mammalian target of rapamycin signaling is sufficient to induce skeletal muscle hypertrophy, Mol Biol Cell, 21, 3258, 10.1091/mbc.e10-05-0454 · DOI · Paper page
- Goodman, 2011, Novel insights into the regulation of skeletal muscle protein synthesis as revealed by a new nonradioactive in vivo technique, FASEB J, 25, 1028, 10.1096/fj.10-168799 · DOI · Paper page
- Goodman, 2012, Muscle fiber type-dependent differences in the regulation of protein synthesis, PLoS ONE, 7, e37890, 10.1371/journal.pone.0037890 · DOI · Paper page
- Schiro, 2011, Mutations in protein-binding hot-spots on the hub protein Smad3 differentially affect its protein interactions and Smad3-regulated gene expression, PLoS ONE, 6, e25021, 10.1371/journal.pone.0025021 · DOI
- Gomes, 2001, Atrogin-1, a muscle-specific F-box protein highly expressed during muscle atrophy, Proc Natl Acad Sci U S A, 98, 14440, 10.1073/pnas.251541198 · DOI · Paper page
- Foletta, 2011, The role and regulation of MAFbx/atrogin-1 and MuRF1 in skeletal muscle atrophy, Pflügers Arch, 461, 325, 10.1007/s00424-010-0919-9 · DOI · Paper page
- McFarlane, 2006, Myostatin induces cachexia by activating the ubiquitin proteolytic system through an NF-κB-independent, FoxO1-dependent mechanism, J Cell Physiol, 209, 501, 10.1002/jcp.20757 · DOI · Paper page
- Handschin, 2010, Regulation of skeletal muscle cell plasticity by the peroxisome proliferator-activated receptor γ coactivator 1α, J Recept Signal Transduct Res, 30, 376, 10.3109/10799891003641074 · DOI · Paper page
- Murphy, 2010, Antibody-directed myostatin inhibition in 21-mo-old mice reveals novel roles for myostatin signaling in skeletal muscle structure and function, FASEB J, 24, 4433, 10.1096/fj.10-159608 · DOI · Paper page
- Samarakoon, 2013, TGF-β signaling in tissue fibrosis: redox controls, target genes and therapeutic opportunities, Cell Signal, 25, 264, 10.1016/j.cellsig.2012.10.003 · DOI · Paper page
- Zhou, 2010, Targeting fibrosis in Duchenne muscular dystrophy, J Neuropathol Exp Neurol, 69, 771, 10.1097/NEN.0b013e3181e9a34b · DOI · Paper page
- Suelves, 2005, The plasminogen activation system in skeletal muscle regeneration: antagonistic roles of urokinase-type plasminogen activator (uPA) and its inhibitor (PAI-1), Front Biosci, 10, 2978, 10.2741/1754 · DOI · Paper page
- Dennler, 1998, Direct binding of Smad3 and Smad4 to critical TGF[beta]-inducible elements in the promoter of human plasminogen activator inhibitor-type 1 gene, EMBO J, 17, 3091, 10.1093/emboj/17.11.3091 · DOI · Paper page
- Naderi, 2009, Plasminogen activator inhibitor type 1 up-regulation is associated with skeletal muscle atrophy and associated fibrosis, Am J Pathol, 175, 763, 10.2353/ajpath.2009.081009 · DOI
- Koh, 2005, Mice deficient in plasminogen activator inhibitor-1 have improved skeletal muscle regeneration, Am J Physiol Cell Physiol, 289, C217, 10.1152/ajpcell.00555.2004 · DOI · Paper page
- van Rooij, 2008, Dysregulation of microRNAs after myocardial infarction reveals a role of miR-29 in cardiac fibrosis, Proc Natl Acad Sci U S A, 105, 13027, 10.1073/pnas.0805038105 · DOI · Paper page
- He, 2013, MicroRNA-29 family, a crucial therapeutic target for fibrosis diseases, Biochimie, 95, 1355, 10.1016/j.biochi.2013.03.010 · DOI · Paper page
- Greco, 2009, Common micro-RNA signature in skeletal muscle damage and regeneration induced by Duchenne muscular dystrophy and acute ischemia, FASEB J, 23, 3335, 10.1096/fj.08-128579 · DOI · Paper page
- Goldstein, 2010, Mechanisms of muscle weakness in muscular dystrophy, J Gen Physiol, 136, 29, 10.1085/jgp.201010436 · DOI
- Lipina, 2010, Mechanisms involved in the enhancement of mammalian target of rapamycin signalling and hypertrophy in skeletal muscle of myostatin-deficient mice, FEBS Lett, 584, 2403, 10.1016/j.febslet.2010.04.039 · DOI · Paper page
- Rena, 1999, Phosphorylation of the transcription factor forkhead family member FKHR by protein kinase B, J Biol Chem, 274, 17179, 10.1074/jbc.274.24.17179 · DOI · Paper page
- Zhao, 2005, Structure and function of the upstream promotor of the human Mafbx gene: The proximal upstream promotor modulates tissue-specificity, J Cell Biochem, 96, 209, 10.1002/jcb.20468 · DOI
- Gomis, 2006, A FoxO-Smad synexpression group in human keratinocytes, Proc Natl Acad Sci U S A, 103, 12747, 10.1073/pnas.0605333103 · DOI · Paper page
- Wang, 2010, Atrogin-1 affects muscle protein synthesis and degradation when energy metabolism is impaired by the anti-diabetic drug, berberine, Diabetes, 59, 1879, 10.2337/db10-0207 · DOI
- Romanello, 2010, Mitochondrial biogenesis and fragmentation as regulators of muscle protein degradation, Curr Hypertens Rep, 12, 433, 10.1007/s11906-010-0157-8 · DOI
- Liu, 2013, Myostatin induces mitochondrial metabolic alteration and typical apoptosis in cancer cells, Cell Death Dis, 4, e494, 10.1038/cddis.2013.31 · DOI
- Chalhoub, 2009, 2009 PTEN and the PI3-kinase pathway in cancer, Annu Rev Pathol, 4, 127, 10.1146/annurev.pathol.4.110807.092311 · DOI · Paper page
- Ge, 2011, Smad3 signaling is required for satellite cell function and myogenic differentiation of myoblasts, Cell Res, 21, 1591, 10.1038/cr.2011.72 · DOI
Cited by
Skeletal muscle atrophy and the E3 ubiquitin ligases MuRF1 and MAFbx/atrogin-1
Bodine, S. C., & Baehr, L. M. (2014) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00204.2014 · Cited by 1,113
Mechanisms of IGF-1-Mediated Regulation of Skeletal Muscle Hypertrophy and Atrophy
Yoshida, T., & Delafontaine, P. (2020) · Cells · doi:10.3390/cells9091970 · Cited by 714
Single-nucleus RNA-seq identifies transcriptional heterogeneity in multinucleated skeletal myofibers
Petrany, M. J., Swoboda, C. O., Sun, C., Chetal, K., Chen, X., Weirauch, M. T., Salomonis, N., & Millay, D. P. (2020) · Nature Communications · doi:10.1038/s41467-020-20063-w · Cited by 389
Cancer cachexia: molecular mechanisms and treatment strategies
Setiawan, T., Sari, I. N., Wijaya, Y. T., Julianto, N. M., Muhammad, J. A., Lee, H., Chae, J. H., & Kwon, H. Y. (2023) · Journal of Hematology & Oncology · doi:10.1186/s13045-023-01454-0 · Cited by 315
TGFβ and BMP signaling in skeletal muscle: potential significance for muscle-related disease
Sartori, R., Gregorevic, P., & Sandri, M. (2014) · Trends in Endocrinology & Metabolism · doi:10.1016/j.tem.2014.06.002 · Cited by 177
Metadata
- Authors
- Goodman, C. A., McNally, R. M., Hoffmann, F. M., & Hornberger, T. A.
- Venue
- Molecular Endocrinology
- Publisher
- The Endocrine Society
- Published
- 2013-11-01
- Volume
- 27
- Issue
- 11
- Pages
- 1946-1957
- ISSN
- 0888-8809 (ISSN-L)
- 1944-9917
- OpenAlex
- W2000066959
- Cited by
- 138
- References
- 24
- FWCI
- 3.50
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.